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Introduction: Extrapleural pneumonectomy has been well de-
fined; however, surgeons vary regarding the surgical extent and
goals of “pleurectomy/decortication” (P/D). We explored meso-
thelioma surgeons’ concepts of P/D with the aim of unifying
surgical nomenclature.
Methods: A web-based survey was administered to surgeons who
operated on malignant pleural mesothelioma (MPM) for diagnosis,
staging, palliation, or cytoreduction. One hundred thirty surgeons
from 59 medical centers were included. Surgeons who did not
perform surgery for MPM within the last year were excluded.
Results: There were 62 (48%) respondents from 39 medical centers in
14 countries. The mean number of patients with MPM seen annually at
each medical center was 46, and the mean annual number of cytore-
ductive procedures performed per surgeon was 8. Most (88%) agreed
that the goal of cytoreductive surgery should be macroscopic complete
resection of tumor. P/D was defined as resection of parietal and visceral
pleura with the aim of achieving macroscopic complete resection by
72% of respondents. If the diaphragm or pericardium required resec-
tion, 64% preferred the term “radical P/D,” whereas “P/D” (40%) or
“total pleurectomy” (39%) was preferred if these structures were not
removed. Most surgeons believed that extrapleural pneumonectomy
(90%) or “radical P/D” (68%) could provide adequate cytoreduction,
whereas only 23% thought that P/D could.
Conclusions: There was significant variation regarding surgical
nomenclature for procedures for MPM. The International Staging
Committee of the International Association for the Study of Lung
Cancer and the International Mesothelioma Interest Group recom-
mend that P/D should aim to remove all macroscopic tumor involv-
ing the parietal and visceral pleura and should be termed “extended”
P/D when the diaphragm or pericardium is resected.
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Surgery for malignant pleural mesothelioma (MPM) mayinclude relatively minor procedures for diagnosis and
staging, more involved debulking operations for palliation,
and extensive cytoreductive procedures where the goal is to
lengthen survival by reducing the intrathoracic tumor burden
to microscopic levels. The latter is usually accomplished
either by extrapleural pneumonectomy (EPP) or by a proce-
dure that is presently classified as “pleurectomy/decortica-
tion” (P/D), generally as part of a multimodality treatment
regimen. Although the surgical technique of EPP has been
standardized, there is a variation among surgeons with re-
spect to what is involved in P/D.1–5 For some mesothelioma
surgeons, P/D refers to a surgical procedure that aims to
remove all macroscopic tumor from the affected hemithorax.6
This typically includes resection of the entire parietal and
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visceral pleura, with resection of portions of the pericardium
and diaphragm if involved by tumor. Others refer to this exten-
sive procedure as a “radical” P/D, reserving the term P/D for
resection of only the parietal and visceral pleura.7,8 Still others
use the term P/D to describe a palliative procedure where the
intention is debulking of tumor to ameliorate pain and pleural
effusion and improve respiratory mechanics.9 Occasionally, op-
erative reports will describe P/D when little more than a thora-
cotomy and generous pleural biopsy has been performed.
In collaboration with the International Mesothelioma
Interest Group (IMIG), the International Association for the
Study of Lung Cancer (IASLC) recently formed a subcom-
mittee of the International Staging Committee to improve the
current staging system for MPM. The mesothelioma subcom-
mittee “Mesothelioma Domain” of the International Staging
Committee recently completed an analysis of a large retro-
spective database and is now developing an international,
multidisciplinary, and multi-institutional cohort study that
will collect information on extent of disease, personal and
demographic characteristics, comorbid illness, treatment, and
survival of newly diagnosed patients with MPM. Because there
is considerable variation regarding the surgical management of
mesothelioma, and in particular P/D, the mesothelioma subcom-
mittee thought that it was important to arrive at definitions of
surgical procedures for MPM that would be unambiguous and
broadly acceptable to most thoracic surgeons. To arrive at a
consensus regarding surgical definitions, a survey was con-
ducted among surgeons who perform surgery for MPM.
METHODS
A web-based questionnaire was created by members of
the IASLC mesothelioma subcommittee using a commercially
available, online survey designer (www.surveymonkey.com).
Unlike a recent survey of surgical opinion in mesothelioma,
which included thoracic surgeons regardless of their level of
experience with the disease, we polled only surgeons who
had a clinical or research interest in MPM and who were
presumed able to offer expert opinion.10,11 Surgeons were
identified by having published on MPM during the past 5
years, by affiliation with a medical center known to specialize
in MPM, by affiliation with the IMIG, or by peer reference.
One hundred thirty surgeons from 59 centers worldwide were
identified and asked to complete the electronic survey. The
survey was designed to examine prevailing views about
nomenclature for various surgical resections commonly per-
formed for pleural mesothelioma and concepts regarding
cytoreduction (Figures. 1–4). In addition to multiple-choice
options, most questions also offered respondents an opportu-
nity to add text-based comments. We explored opinions
regarding use of the terms “partial pleurectomy,” “pleurec-
tomy/decortication,” “total pleurectomy,” and “radical pleurec-
tomy/decortication.” Because EPP has been standardized from a
procedural standpoint, we did not further explore terminology
for this operation. The survey collected data over a 3-week
period from October 11 through October 29, 2010. Two remind-
ers were sent electronically to participants during this period.
Responses from thoracic surgeons who did not perform any type
of surgery for MPM (including either surgery for diagnosis,
staging, palliation, and/or cytoreduction) were censored from
further analysis. Responses were analyzed according to the raw
data, and results were reviewed with the members of the IASLC
Mesothelioma Domain and the Advisory Board, and consensus
achieved before the manuscript was prepared. It was then sub-
mitted to all members of the IASLC Staging Committee and to
board members of the IMIG for approval before the manuscript
and recommendations were finalized.
RESULTS
Respondents
The survey was sent through email to 130 thoracic
surgeons, of which 62 (47.7%) responded. Respondents were
affiliated with 39 different medical centers in 14 countries.
Most were from centers in Europe (47%) or North America
(42%) with only six (10%) responders from Asia and one
from Australia (Table 1). Three participants did not perform
any type of surgery for MPM and were censored from further
analysis (Figure 1). One respondent provided incomplete data
leaving a total of 58 respondents who provided analyzable
data. The mean number of patients with MPM seen annually
at participating centers was 40 (median, 32; range, 3–150),
and the mean number of mesothelioma surgical cases annu-
ally performed by respondents (n  58) was 20 (median, 16;
range, 2–80). Ninety-eight percent of surgeons performed
surgery for diagnosis, 82% for surgical staging, 85% per-
formed cytoreductive surgery, and 71% performed surgery
for palliation. Only 34 of 58 surgeons (59%) performed
surgery for all four indications. Three (5%) surgeons per-
formed palliative surgery but not cytoreductive surgery. Of
surgeons who practiced cytoreductive surgery (n  49), the
mean number of cases performed within the 12-month period
preceding the survey was 10.4 (range, 1–30).
Surgical Definitions
Most respondents (95%) felt that there was a need to
refine surgical nomenclature to account for the procedural
differences between P/D for palliation and P/D performed for
macroscopic complete resection (MCR) or maximal cytore-
duction (Figure 2). Thirty-nine of 58 (67%) respondents
defined “partial pleurectomy” as a partial debulking of tumor
for palliative purposes. Of these, 21 (36%) considered it to
include resection of both parietal and visceral tumor, whereas
the others considered it to include removal of only parietal
tumor. Ten (17%) surgeons considered “partial pleurectomy”
to be a subtotal removal of parietal and visceral tumor for
palliation with the expectation of leaving gross residual
disease behind, and another four (7%) defined the procedure
as the removal of all gross parietal and visceral tumor with
the intention of achieving an R0 or R1 resection without
removal of the diaphragm or pericardium. Only three (5%)
respondents felt that it should be defined as resection of
parietal pleura for diagnostic purposes only. Forty-two of 58
(72%) respondents considered the term “P/D” to imply re-
section of all gross parietal and visceral tumor with the
objective of achieving resection of all macroscopic disease.
Of these, 18 (31%) considered the procedure to also include
resection of the diaphragm and/or pericardium even if in-
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volved by tumor. Nevertheless, 15 (26%) surgeons consid-
ered “P/D” to be a subtotal removal of parietal and visceral
tumor for palliation with the expectation of leaving gross
residual disease behind (R2), and one (2%) respondent de-
fined the procedure as a partial debulking of parietal and
visceral tumor for palliation.
FIGURE 1. Questions 1 to 5. Demographic and practice information of the respondents.
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To further explore opinions regarding the extent of
“P/D,” two scenarios were provided where the intent was
to resect parietal and visceral tumor so that no residual
macroscopic tumor remained (Figure 3). In one scenario,
the diaphragm and pericardium were resected, and in the
other scenario they were not. With regard to the first
(diaphragm and/or pericardial resection), the majority
(64%) referred to the procedure as “radical P/D.” Eleven
(19%) surgeons preferred the term “total pleurectomy” and
only three (5%) used “P/D.” One surgeon considered this
a “partial resection.” To describe the second scenario (no
diaphragm or pericardial resection), 23 (40%) chose the
term “P/D,” whereas 22 (39%) preferred “total pleurec-
tomy.” Only six (10.5%) surgeons called this procedure a
FIGURE 2. Questions 6 to 8. Opinions regarding definition of partial pleurectomy and pleurectomy/decortication.
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“radical P/D.” Two (3.4%) respondents used the term
“palliative debulking” and another two (3.4%) used “par-
tial pleurectomy.” One (1.7%) respondent preferred the
term “subtotal P/D.”
Cytoreduction
Fifty-one (88%) respondents agreed with the premise
that the goal of cytoreductive surgery in MPM should be the
removal of all visible or palpable tumor (R0 or R1) or a
“macroscopic complete resection” (MCR) (Figure 4). When
asked which cytoreductive procedure was capable of provid-
ing MCR, 51 (90%) chose EPP and 39 (68%) “radical P/D,”
but only 13 (23%) thought that “P/D” could. One of the
factors that influence performance of P/D versus EPP is
whether tumor involves the fissures. Twenty-two (38%) re-
spondents agreed that P/D could usually provide a MCR if
tumor involved the fissure, however, 30 (51%) did not. In
addition, the majority of respondents (86%) did not believe
that video-assisted thoracoscopic surgery was capable of
providing as complete a cytoreduction as an open procedure.
Nevertheless, three (5%) respondents did, and another agreed
that it could in patients with stage I disease. The remaining
four respondents were uncertain.
FIGURE 3. Questions 9 to 11. Opinions regarding the surgical extent of pleurectomy/decortication.
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FIGURE 4. Questions 12 to 15. Opinions regarding surgical goals and technical ability to achieve macroscopic complete re-
section.
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DISCUSSION
The first description of P/D is attributed to Fowler12
who reported the successful treatment of a man with chronic
empyema and bronchopleural fistula in 1893. Nevertheless, it
was not until 20 years later when four patients successfully
underwent P/D at the Mayo Clinic that the procedure began
to gain popularity and gradually superceded thoracoplasty as
the preferred method for the initial treatment for chronic
empyema and trapped lung.13 It is worth noting that “decor-
tication” involved freeing of the fibrinous rind away from the
visceral pleura and not resection of the visceral pleura itself.
In the 1950s and 1960s, parietal pleurectomy was used for the
treatment of spontaneous pneumothorax,14,15 and in 1963,
Jensik et al.16 at the University of Chicago reported the use of
parietal pleurectomy for treatment of malignant pleural effu-
sions, showing a 96% freedom from recurrence in 50 patients.
As meticulously described by Beattie,17 parietal pleurectomy
began with creation of an extrapleural plane before insertion
of a rib spreader, with continued dissection “up over the apex
of the thoracic cavity, and down to and around the lung
hilum.” Once the upper half of the parietal pleura had been
freed, it was excised, and the lower half then dissected down
to the costophrenic sulcus. It was noted that it was usually
impossible to remove the diaphragmatic pleura which was
left attached to the intact diaphragm.
The first report of pleural resection for MPM was by
Martini et al.18 in 1975 who described outcomes of parietal
pleurectomy in 83 patients with malignant pleural effusions,
of which 14 had mesothelioma. At 1 year, 79% of patients
were noted to have been alive, with little or no clinical
limitation in pulmonary reserve, and the median survival of
those with MPM was 16 months. A year later, this series was
expanded to include 33 patients with MPM who had a median
survival of 21 months. It should be noted that in these early
descriptions of pleurectomy for mesothelioma “all pleura
covering the rib cage and mediastinum (was) removed,” but
attempts were not made to remove the visceral pleura or
resection of the diaphragm or pericardium.19 The operation
became referred to as “subtotal parietal pleurectomy” as
neither the visceral, diaphragmatic nor pericardial pleurae
were removed.20
Coincidentally, EPP (also termed pleuropneumonec-
tomy) for MPM began to be performed, its proponents argu-
ing that pleurectomy could not possibly achieve the same
degree of tumor clearance as EPP, largely because with
pleurectomy tumor frequently remained on the diaphragm,
pericardium, and the visceral surfaces and fissures of the
lung.21,22 Perhaps in response to this challenge, pleurectomy
evolved in some surgeons’ hands into a more extensive
procedure than had been described previously. In 1989,
Rusch and Livingston23,24 described “radical decortication”
in conjunction with intrapleural chemotherapy and, in the
article that followed, P/D was defined as parietal pleurectomy
with either partial or complete visceral pleurectomy accord-
ing to the extent of tumor involvement. The diaphragm and/or
pericardium were frequently resected and reconstructed but
with preservation of the underlying peritoneum. Variations
on this theme have been reported by others, the common
thread being resection of tumor involved parietal and visceral
pleurae.25 In one of the larger and more recent series, Rich-
ards et al.4 from the Brigham and Women’s Hospital de-
scribed P/D as resection of the parietal and visceral pleurae
along with involved areas of the pericardium and diaphragm. As
described by others, the intended goal was to obtain a MCR,
arbitrarily defined as tumor residual less than 1.0 cm.3,5,26 The
clear intent of these cytoreductive procedures is to resect all
gross tumor while preserving underlying lung parenchyma.
This has not gained unanimous acceptance however. For
example, Butchart9 has referred to P/D as “debulking”
surgery which did not include resection of the diaphragm.
The term P/D is still frequently applied to procedures that
remove some parietal and visceral pleural tumor and yet
which are strictly palliative in intent leaving behind con-
siderable amounts of gross tumor. Perhaps, this is why in
an effort to differentiate the more intensive cytoreductive
procedure from less extensive ones several authors have
recently applied the qualifier “radical” when referring to a
maximally cytoreductive P/D.7,8 Thus, 35 years after the
initial description, there remains some ambiguity regard-
ing the definition of P/D for MPM.
The overall response rate to our survey was less than
50% but is on a par with response rates of other recent
web-based surgical surveys. The thoracic surgeons who com-
pleted the survey were experienced in MPM surgery—per-
forming what would be considered a high volume of opera-
tions for this rare disease. Respondents were primarily from
North America and Europe, so it can be argued that the
findings may be biased toward Western practice, but this
primarily reflects the incidence of MPM and the geographic
location of centers involved in surgical and multimodality
treatment for MPM. The survey confirmed significant varia-
tion among thoracic surgeons regarding the definition of P/D.
When pleural resection was performed for palliative pur-
poses, most respondents did not refer to the procedure as
“P/D” but rather used terms such as partial pleurectomy,
palliative debulking, or palliative P/D. Thus, based on the
TABLE 1. Geographic Distribution of Physicians Who
Responded to the Online Survey
Country No. of Responses Percentage
United States 23 37.1
United Kingdom 10 16.1
Japan 6 9.7
Italy 5 8.1
Spain 3 4.8
Canada 3 4.8
Turkey 2 3.2
Switzerland 2 3.2
Germany 2 3.2
Belgium 2 3.2
Greece 1 1.6
Australia 1 1.6
Netherlands 1 1.6
France 1 1.6
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findings of the survey, P/D seems to imply a level of com-
pleteness or thoroughness of tumor resection that did not
apply to debulking or palliative procedures. Nevertheless,
when the diaphragm or pericardium had to be resected to
achieve MCR, most surgeons (64%) favored the term “radi-
cal” P/D.
Finally, we explored the opinion regarding complete-
ness of resection achievable with surgery for mesothelioma.
The majority of surgeons polled believed that MCR should be
the goal of cytoreductive surgery, regardless of whether that
involves EPP or a lung-preserving operation. This is certainly
in line with the current surgical philosophy of high-volume
centers.3,5,26 Furthermore, most agreed that either “radical P/D”
or EPP could provide MCR in appropriately selected patients,
but most responders did not consider that P/D (without dia-
phragm or pericardial resection) could do so. Nevertheless, this
clearly depends on the extent of the disease.
RECOMMENDATION
On the basis of the survey data, which represented the
opinions of experienced MPM surgeons from multiple cen-
ters in different geographical regions, the IASLC Mesotheli-
oma Domain and the IMIG have recommended the following
terminology to be used in the forthcoming Mesothelioma
Staging Project:
a. EPP: en bloc resection of the parietal and visceral pleura
with the ipsilateral lung, pericardium, and diaphragm. In
cases where the pericardium and/or diaphragm are not
involved by tumor, these structures may be left intact.
b. Extended P/D: parietal and visceral pleurectomy to
remove all gross tumor with resection of the diaphragm
and/or pericardium. The IASLC Mesothelioma Domain
suggests use of the term “extended” rather than “radi-
cal” in this instance as the latter implies a completeness
of resection with added therapeutic benefit. There is
currently insufficient evidence that resection of the
pericardium and diaphragm provides either.
c. P/D: parietal and visceral pleurectomy to remove all
gross tumor without diaphragm or pericardial resection.
d. Partial pleurectomy: partial removal of parietal and/or
visceral pleura for diagnostic or palliative purposes but
leaving gross tumor behind.
APPENDIX A: IASLC INTERNATIONAL STAGING
COMMITTEE
Peter Goldstraw, Past Chair, Royal Brompton Hospital
and Imperial College, London, United Kingdom; Ramo´n
Rami-Porta, Chair, Hospital Universitari Mutua Terrassa,
Terrassa, Spain; Hisao Asamura, Chair Elect, National Can-
cer Center, Tokyo, Japan; David Ball, Peter MacCallum
Cancer Institute, Melbourne, Australia; David Beer, Univer-
sity of Michigan, Ann Arbor, Michigan; Elisabeth Brambilla,
Centre Hospitalier Universitaire Albert Michallon, Grenoble,
France; Vanessa Bolejack, Cancer Research and Biostatistics,
Seattle, Washington; Paul Bunn, Ex Office, University of
Colorado Cancer Center, Aurora, Colorado; Kari Chansky,
Cancer Research and Biostatistics, Seattle, Washington; John
Crowley, Cancer Research and Biostatistics, Seattle, Wash-
ington; Frank Detterbeck, Yale University, New Haven, Con-
necticut; Wilfried Eberhardt, University of Essen, Essen,
Germany; John Edwards, Northern General Hospital, Shef-
field, United Kingdom; Franc¸oise Galateau-Salle´, Centre
Hospitalier Universitaire, Caen, France; David Gandara, Ex
Office, University of California Davis Cancer Center, Sacra-
mento, California; Dorothy Giroux, Cancer Research and
Biostatistics, Seattle, Washington; Fergus Gleeson, Churchil
Hospital, Oxford, United Kingdom; Patti Groome, Queen’s
Cancer Research Institute, Kingston, Ontario, Canada; James
Huang, Memorial Sloan-Kettering Cancer Center, New York
City, New York; James Jett, Ex Office, National Jewish
Health, Denver, Colorado; Catherine Kennedy, University of
Sydney, Sydney, Australia; Jhingook Kim, Samsung Medical
Center, Seoul, Korea; Haruhiko Kondo, Shizuoka Cancer
Center, Shizuoka, Japan; Mark Krasnik, Gentofte Hospital,
Copenhagen, Denmark; Diana Lowry, Cancer Research and
Biostatistics, Seattle, Washington; Jan van Meerbeeck, Uni-
versity Hospital, Ghent, Belgium; Takashi Nakano, Hyogo
College of Medicine, Hyogo, Japan; Andrew Nicholson,
Royal Brompton Hospital, London, United Kingdom; Anna
Nowak, University of Western Australia, Subiaco, Australia;
Harvey Pass, Board Liaison, New York University, New
York, New York; Michael Peake, Glenfield Hospital, Leic-
ester, United Kingdom; Pieter Postmus, Free University Med-
ical Center, Amsterdam, The Netherlands; Thomas Rice,
Cleveland Clinic, Cleveland, Ohio; Kenneth Rosenzweig,
Mount Sinai Hospital, New York, New York; Valerie Rusch,
Memorial Sloan-Kettering Cancer Center, New York, New
York; Nagahiro Saijo, National Cancer Center Hospital East,
Chiba, Japan; Paul van Schil, Antwerp University Hospital,
Edegem (Antwerp), Belgium; Jean-Paul Sculier, Institut Jules
Bordet, Brussels, Belgium; Leslie Sobin, Armed Forces In-
stitute of Pathology, Washington, DC; Charles Thomas, Or-
egon Health & Science University, Portland, Oregon; Charles
F. Thomas Jr, Mayo Clinic, Rochester, Minnesota; William
Travis, Memorial Sloan-Kettering Cancer Center, New York,
New York; Ming Tsao, The Princess Margaret Hospital,
Toronto, Ontario, Canada; Masahiro Tsuboi, Board Liaison,
Kanagawa Cancer Center, Yokohama, Japan; Andrew Tur-
risi, Sinai Grace Hospital, Detroit, Michigan; Eric Vallie´res,
Swedish Cancer Institute, Seattle, Washington; Johan Vans-
teenkiste, University Hospitals, Leuven, Belgium; Hirokazu
Watanabe, National Cancer Center Hospital, Tokyo, Japan;
and Yi-Iong Wu, Guangdong Provincial Peoples Hospital,
Guangzhou, People’s Republic of China.
APPENDIX B: INTERNATIONAL
MESOTHELIOMA INTEREST GROUP (IMIG)
BOARD MEMBERS
Steve Albelda, University of Pennsylvania, Philadel-
phia, Pennsylvania; Sam Armato, The University of Chicago
Medical Center, Chicago, Illinois; Paul Baas, The Nether-
lands Cancer Institute, Amsterdam, The Netherlands; Court-
ney Broaddus, University of California San Francisco, San
Francisco, California; Dean Fennell, Queen’s University Bel-
fast, Belfast, Northern Ireland, United Kingdom; Rabab Gaa-
Journal of Thoracic Oncology • Volume 6, Number 8, August 2011 Recommendations for Uniform Definitions
Copyright © 2011 by the International Association for the Study of Lung Cancer 1311
far, Cairo University, Cairo, Egypt; Marie-Claude Jaurand,
Institut National de la Sante´ et de la Recherche Me´dicale,
Paris, France; Hedy Kindler, The University of Chicago
Medical Center, Chicago, Illinois; Sakari Knuutila, Univer-
sity of Helsinki, Helsinki, Finland; Steven Mutsaers, Univer-
sity of Western Australia, Perth, Australia; Luciano Mutti,
Vercelli Hospital, Vercelli, Italy; Takashi Nakano, Hyogo
College of Medicine, Hyogo, Japan; Harvey Pass, New York
University, New York, New York; Bruce Robinson, Univer-
sity of Western Australia, Perth, Australia; Jeremy Steele, St
Bartholomew’s Hospital, London, United Kingdom; Daniel
Sterman, University of Pennsylvania, Philadelphia, Pennsyl-
vania; Jim teWaterNaude, University of Cape Town, Cape
Town, South Africa; and Walter Weder, University Hospital
Zurich, Zurich, Switzerland.
APPENDIX C: ADVISORY BOARD OF THE IASLC
MESOTHELIOMA DOMAIN
Paul Baas, The Netherlands Cancer Institute, Amster-
dam, The Netherlands; Jeremy Erasmus, M. D. Anderson
Cancer Center, Houston, Texas; Seiki Hasegawa, Hyogo
College of Medicine, Hyogo, Japan; Kouki Inai, Hiroshima
University Postgraduate School, Hiroshima, Japan; Kemp
Kernstine, City of Hope, Duarte, California; Hedy Kindler,
The University of Chicago Medical Center, Chicago, Illinois;
Lee Krug, Memorial Sloan-Kettering Cancer Center, New
York, New York; Kristiaan Nackaerts, University Hospitals,
Leuven, Belgium; and David Rice, M. D. Anderson Cancer
Center, Houston, Texas.
REFERENCES
1. Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodal-
ity treatment of malignant pleural mesothelioma: extrapleural pneumo-
nectomy and pleurectomy/decortication. Semin Thorac Cardiovasc Surg
2009;21:132–148.
2. Sugarbaker DJ, Richards WG, Garcia JP. Extrapleural pneumonectomy
for malignant mesothelioma. Adv Surg 1997;31:253–271.
3. Sugarbaker DJ, Wolf AS. Surgery for malignant pleural mesothelioma.
Expert Rev Respir Med 2010;4:363–372.
4. Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurec-
tomy/decortication and intraoperative intracavitary hyperthermic cispla-
tin lavage for mesothelioma. J Clin Oncol 2006;24:1561–1567.
5. Pass H. Surgery and mesothelioma: if not randomization, at least
standardization and registration! Lung Cancer 2011;71:1–2.
6. Rusch VW. Pleurectomy/decortication and adjuvant therapy for malig-
nant mesothelioma. Chest 1993;103(Suppl 4):382S–384S.
7. Bo¨lukbas S, Manegold C, Eberlein M, et al. Survival after trimodality
therapy for malignant pleural mesothelioma: radical pleurectomy, che-
motherapy with cisplatin/permetrexed and radiotherapy. Lung Cancer
2011;71:75–81.
8. Nakas A, Trousse DS, Martin-Ucar AE, et al. Open lung-sparing surgery
for malignant pleural mesothelioma: the benefits of a radical approach
within multimodality therapy. Eur J Cardiothorac Surg 2008;34:886–
891.
9. Butchart EG. Contemporary management of malignant pleural mesothe-
lioma. Oncologist 1999;4:488–500.
10. Treasure T, Internullo E, Fiorentino F, et al. A survey of opinions and
beliefs concerning surgery for malignant pleural mesothelioma amongst
802 members of the European Association for Cardio-Thoracic Surgery
(EACTS), the European Society of Thoracic Surgeons (ESTS) and the
Society of Thoracic Surgeons (STS). Interact Cardiovasc Thorac Surg
2011;12:341–346.
11. Rena O, Casadio C. Lack of evidence in malignant pleural mesothelioma
surgery. Interact Cardiovasc Thorac Surg 2011;12:347–348.
12. Fowler. Med Rec 1893;30:838–839.
13. Mayo CH, Beckman EH. X. Visceral pleurectomy for chronic empyema.
Ann Surg 1914;59:884–890.
14. Gaensler EA. Parietal pleurectomy for recurrent spontaneous pneumo-
thorax. Surg Gynecol Obstet 1956;102:293–308.
15. Thomas PA, Gebauer PW. Results and complications of pleurectomy for
bullous emphysema and recurrent pneumothorax. J Thorac Cardiovasc
Surg 1960;39:194–201.
16. Jensik R, Cagle JE Jr, Milloy F, et al. Pleurectomy in the treatment of
pleural effusion due to metastatic malignancy. J Thorac Cardiovasc
Surg 1963;46:322–330.
17. Beattie EJ Jr. The treatment of malignant pleural effusions by partial
pleurectomy. Surg Clin North Am 1963;43:99–108.
18. Martini N, Bains MS, Beattie EJ Jr. Indications for pleurectomy in
malignant effusion. Cancer 1975;35:734–738.
19. Wanebo HJ, Martini N, Melamed MR, et al. Pleural mesothelioma.
Cancer 1976;38:2481–2488.
20. McCormack PM, Nagasaki F, Hilaris BS, et al. Surgical treatment of
pleural mesothelioma. J Thorac Cardiovasc Surg 1982;84:834–842.
21. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in
the management of diffuse malignant mesothelioma of the pleura.
Experience with 29 patients. Thorax 1976;31:15–24.
22. DeLaria GA, Jensik R, Faber LP, et al. Surgical management of
malignant mesothelioma. Ann Thorac Surg 1978;26:375–382.
23. Rusch V, Livingston R. Radical decortication, intraoperative intrapleural
cisplatin (CDDP) and post-operative systemic chemotherapy for malig-
nant pleural mesothelioma (MM). Proc Am Soc Clin Oncol 1989;8:219.
24. Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/
decortication followed by intrapleural and systemic chemotherapy for
malignant pleural mesothelioma. J Clin Oncol 1994;12:1156–1163.
25. Lee JD, Perez S, Wang HJ, et al. Intrapleural chemotherapy for patients
with incompletely resected malignant mesothelioma: the UCLA experi-
ence. J Surg Oncol 1995;60:262–267.
26. Flores RM. Surgical options in malignant pleural mesothelioma: extra-
pleural pneumonectomy or pleurectomy/decortication. Semin Thorac
Cardiovasc Surg 2009;21:149–153.
Rice et al. Journal of Thoracic Oncology • Volume 6, Number 8, August 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1312
